HCRT and insomnia: The most extensive clinical safety data available on an orexin antagonist is for suvorexant, a dual orexin-receptor (OX1R/OX2R) antagonist (DORA), which was approved in the United States (US) and Japan in 2014 for the treatment of insomnia.